VolitionRx reported strong 112% H1 revenue growth and significant progress across its product pipeline, including advancements in sepsis detection, lung cancer reimbursement, and a veterinary cancer test. The company also announced a new collaboration with Sysmex Corporation and active licensing discussions, indicating potential for future growth and market expansion.
VolitionRx (VNRX) announced a robust 112% year-over-year revenue growth for the first half of 2026, reaching $1.4 million. This significant financial improvement is coupled with substantial progress in its product pipeline, including advancements in sepsis diagnostics, European lung cancer reimbursement plans, and the submission of a manuscript for its feline lymphoma test, which could trigger a $5 million milestone payment. The newly announced collaboration with Sysmex Corporation and ongoing licensing discussions with over a dozen diagnostic leaders suggest potential for broader market penetration and future revenue streams. This filing indicates strong operational momentum and positive catalysts for VNRX, offering a short-term positive outlook and long-term growth potential, particularly if licensing deals materialize and the veterinary milestone is achieved.